Get more information on Neuroscience Market - Request Free Sample Report
The Neuroscience Market Size was valued at USD 35.3 billion in 2023 and is expected to reach USD 50.2 Billion by 2032, growing at a CAGR of 4.00% from 2024-2032.
The neuroscience market is witnessing substantial growth, fueled by rising research and development investments, technological advancements, and a deeper understanding of brain functions and disorders. Key focus areas include drug development, mental health, and brain-computer interfaces (BCIs), all of which are contributing to the market's expansion. By 2023, global funding for neuroscience research had exceeded USD 25 billion, with a significant portion allocated to brain health and cognitive enhancement initiatives. The increasing prevalence of neurological conditions like Alzheimer's, Parkinson's, and dementia is a major catalyst for market growth, affecting millions of people globally.
A significant driver of this growth is the escalating demand for advanced diagnostics and treatments for neurological diseases. As the global population ages, the need for therapies addressing cognitive decline has grown considerably. For example, the Alzheimer’s Therapeutics market alone is expected to surpass USD 13.42 billion by 2032, as pharmaceutical companies develop therapies to slow disease progression. Innovations in biomarkers and imaging technologies are advancing early detection and treatment options, further propelling the market forward.
Technological breakthroughs, particularly in artificial intelligence (AI) and machine learning (ML), are revolutionizing neuroscience research and healthcare. AI tools are enabling researchers to process vast amounts of brain data, uncover patterns in brain activity, and refine diagnostic accuracy. Brain-computer interfaces (BCIs) are also gaining traction, providing assistive technologies and rehabilitation solutions for individuals with motor impairments. The BCI market is expected to grow rapidly, driven by advancements in non-invasive EEG-based systems, which make these technologies more affordable and accessible.
Additionally, the focus on mental health has intensified, particularly in the aftermath of the COVID-19 pandemic. Increased funding for research into mental health disorders such as depression, anxiety, and PTSD is ensuring that neuroscience continues to thrive. This heightened attention, combined with continuous technological advancements and greater investment in research, positions the neuroscience market for sustained growth and innovation in the years to come.
Drivers
The growing prevalence of conditions like Alzheimer's, Parkinson's, and dementia is driving demand for innovative therapies and diagnostic tools.
As the elderly population increases, the need for treatments targeting age-related cognitive decline grows, particularly for Alzheimer’s and other neurodegenerative diseases.
The rise of non-invasive BCIs is facilitating rehabilitation and assistive technologies, making them more accessible and cost-effective
Non-Invasive Brain-Computer interfaces (BCIs) are transforming neuroscience market with cheaper, easily accessible solutions in the area of rehabilitation technologies and assistive technology devices. These BCIs enable brain-communication with the outside world without needing a surgical procedure. Such technology has been very promising for patients with motor disabilities secondary to neurological disorders like stroke, cerebral palsy, and spinal cord injury. EEG-based non-invasive systems are rendering importance in the restoration of motor functions, communication & overall quality of life to the patients.
These BCIs have become more affordable over time, as they had previously relied on costly surgical implants. These systems have gained widespread support for various rehabilitation applications, such as prosthetic limb control and communication for locked-in syndrome, and increasingly, both healthcare providers and patients are becoming more familiar with them. More affordable than ever, it will drive adoption at a faster pace across the healthcare sector. Integration of Machine learning (ML) and artificial intelligence (AI) have played an important role in the improvement of non-invasive BCIs. These algorithms enhance the accuracy of mapping macroscale brain signals, enabling real-time control of external devices. When integrated with VR platforms for rehabilitation, Brain-Computer Interfaces (BCIs) are broadening their medical applications, offering innovative solutions in treatment.
With continuous research, rising cases of neurological disorders, and introduction of devices with more intuitive and easy-to-use features, it is anticipated that non-invasive BCIs will continue to flourish. And, these technologies are not just helping people with motor disabilities, they are also providing some benefit when used in the treatment for other neurological disorders, including epilepsy, depression, and anxiety. Recent advances in available non-invasive BCIs promise to significantly reduce their financial burden associated with the cost and implementation of the technology, which will help move BCI into common usage as part of the neurosciences market in rehabilitation and assistive technologies.
Restraints
The approval process for neurological treatments and devices can be lengthy and complex, delaying product launches and market growth.
Technologies like BCIs and genetic research raise ethical issues regarding privacy, consent, and the potential misuse of neuro technologies.
Some neurological treatments, especially experimental ones, may have adverse side effects, impacting patient safety and limiting their use in the market.
In the neuroscience field, many new neurological treatments, especially experimental therapies, are limited by the possibility of adverse side effects, which can be a safety issue and prevent widespread use. These treatments have potential uses in diseases such as Alzheimer, Parkinson and epilepsy, but they pose significant safety hurdles. Clinical trials are necessary for revealing these risks, but they can also find serious side effects that threaten development. The anti-amyloid antibody therapies for Alzheimer's disease had performed well but were associated with adverse events like brain swelling and bleeding, making wide use impossible.
The brain is a highly complex organ and this makes it all the more difficult to predict how things will turn out longer down the line. While intended to suppress individual symptoms, these therapies may unknowingly suppress cognitive functioning, motor skills, or emotional well-being in other areas, sometimes, in ways that cannot easily be predicted. Such unpredictability creates wariness: health professionals and patients alike may shun therapies bringing fresh uncertainties, even if they directly track the target ailment.
Moreover, the existence of these side effects complicates the approval process from a regulatory view. Health authorities such as the FDA and EMA impose extensive safety testing, which frequently delays entry of effective therapies into the market. As such, the prolonged approval times decrease the rate at which novel treatment options can be discovered, which in turn leads to slower growth and impact of the neuroscience industry. This cautious method of regulation safeguards patients but will delay the adoption of cutting-edge therapies into healthcare systems.
Overall, although there is much promise in the ability to develop ground breaking treatments to improve functional recovery from neurologic disease and injury, the potential of experimental therapies is greatly limited by the risk of off-target effects. The challenge hinders their uptake in the market, and slows the progress of neuroscience as a whole.
By Component
In 2023, the instruments segment held the largest share of 65.41%, dominated due to high demand of advanced diagnostics and therapeutics technologies. One such innovative device is the CT 3500, an artificial intelligence-powered computed tomography (CT) scanner that Koninklijke Philips N.V. introduced in May 2023. Ideal for routine radiology and for high-volume screening, this device is aimed to provide imaging with high resolution to assist radiologists to diagnose with higher accuracy.
The consumables segment is expected to gain significant market share over the next few years. Market Growth to be Driven by Durable, Easy-to-Use Consumables for Neurology Procedures from Leader Firms Such as B. Braun SE, GE HealthCare. Moreover, the ongoing availability of new consumables is likely to propel market growth in this segment, and delivery of precise diagnosis and therapeutics.
By Technology
In 2023, the brain imaging segment dominated the market, accounting for 26.07% of the share, driven by the growing application of MRI, EEG, and CT scans in hospitals, diagnostic centers, and ambulatory surgical centers (ASCs) to diagnose neurological conditions. According to the NHS England and NHS Improvement Report, over 67,000 brain MRI referrals were made in March 2022, primarily for cancer diagnosis. This growing reliance on imaging technologies is expected to continue fueling demand in the years ahead.
The neuro-microscopy segment is also set for substantial growth during the forecast period, driven by innovations in the field. For instance, in May 2023, MIT nanotechnologist Deblina Sarkar introduced ultra-small electronic machines capable of entering the brain, which could help detect and potentially reverse neurological disorders. Furthermore, major companies such as Danaher Corporation and Carl Zeiss AG are significantly contributing to the segment’s expansion through their diverse range of neuro-microscopy products, expected to support continued growth in the coming years.
In 2023, North America held the largest share of the neuroscience market, with 32.52%, largely due to the robust presence of companies focused on the development, manufacturing, and commercialization of diagnostic and therapeutic devices for neurological conditions. For instance, Cerenovus also expanded its stroke care portfolio with new liquid embolic systems in March 2024, offering advanced solutions for minimally invasive stroke treatments. These developments underscore the ongoing commitment to enhancing neurovascular technologies for better clinical outcomes.
The Asia Pacific region is projected to experience the fastest growth during the forecast period, driven by rising investments in healthcare infrastructure and increasing healthcare expenditures. A key example of substantial investment in neuroscience is the BRAIN Initiative in the United States, which continues to progress in 2023. Launched by the National Institutes of Health (NIH), this effort aims to map the human brain in remarkable detail, improving the understanding of neurological diseases and driving the development of new treatments. Similarly, In September 2023, the NIH unveiled the BRAIN CONNECTS project, focused on deciphering the neural circuits behind behavior, which could transform how brain disorders are managed. Similar to China's China Brain Project, this initiative is expected to spur breakthroughs in brain research, marking a major leap forward in both understanding and treating neurological conditions.
Need any customization research on Neuroscience Market - Enquiry Now
The major key players are
Johnson & Johnson MedTech - EMBOGUARD Balloon Guide Catheter
Philips Healthcare - Philips Ingenia MRI Scanner
Medtronic - Mazor X Stealth Edition
GE Healthcare - Discovery MI PET/CT Scanner
Siemens Healthineers - SOMATOM X.cite CT Scanner
AbbVie - Vraylar (Cariprazine)
Boston Scientific - Neurovascular Stents
Cerenovus (Johnson & Johnson) - EMBOLIZER Balloon Catheter
NeuroPace - RNS System
Stryker Corporation - Penumbra Aspiration System
Elekta - Unity MR-Linac
Astellas Pharma - Xtandi (Enzalutamide)
NeuroSigma - Monarch eTNS System
Mindmaze - MindMotion GO
Cortech Solutions - NeuraLACE
Baxter International - Brain Anatomy Dissection Kit
Fresenius Medical Care - Fresenius 4008S Hemodialysis Machine (for stroke care)
Illumina - NovaSeq 6000 System
Biogen - Spinraza (Nusinersen)
Abbott Laboratories - Infinity Deep Brain Stimulation (DBS) System
March 2024: Siemens Healthineers introduced an upgraded version of its brain imaging technology, incorporating AI for faster and more accurate diagnostics of neurological diseases such as multiple sclerosis.
January 2024: GE Healthcare launched new advancements in its MRI technology, offering higher resolution imaging for improved brain diagnostics, which is essential for understanding neurological conditions like Alzheimer's disease and brain tumors.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 35.3 Billion |
| Market Size by 2032 | USD 50.2 Billion |
| CAGR | CAGR of 4.00% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Component (Instruments, Consumables, Software & Services) • By End-Use (Hospitals, Diagnostic laboratories, Research and Academic Institute) • By Technology (Brain Imaging, Neuro-Microscopy, Stereotaxic Surgeries, Neuro-Proteomic Analysis, Neuro-Cellular Manipulation, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Johnson & Johnson MedTech, Philips Healthcare, Medtronic, GE Healthcare, Siemens Healthineers, AbbVie, Boston Scientific, Cerenovus (Johnson & Johnson), NeuroPace, Stryker Corporation, Elekta, Astellas Pharma |
| Key Drivers | • The growing prevalence of conditions like Alzheimer's, Parkinson's, and dementia is driving demand for innovative therapies and diagnostic tools. • As the elderly population increases, the need for treatments targeting age-related cognitive decline grows, particularly for Alzheimer’s and other neurodegenerative diseases. |
| RESTRAINTS | • The approval process for neurological treatments and devices can be lengthy and complex, delaying product launches and market growth. • Technologies like BCIs and genetic research raise ethical issues regarding privacy, consent, and the potential misuse of neuro technologies. |
Ans- Neuroscience Market was valued at USD 35.3 billion in 2023 and is expected to reach USD 50.2 Billion by 2032, growing at a CAGR of 4.00% from 2024-2032.
Ans- the CAGR of Neuroscience Market during the forecast period is of 4.00% from 2024-2032.
Ans- The North America dominated the market and represented significant revenue share in 2023
Ans- one main growth factor for the Neuroscience Market is
Ans- Challenges in Neuroscience Market are
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and supply chain strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Neuroscience Market Segmentation, By Component
7.1 Chapter Overview
7.2 Instruments
7.2.1 Instruments Market Trends Analysis (2020-2032)
7.2.2 Instruments Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Consumables
7.3.1 Consumables Market Trends Analysis (2020-2032)
7.3.2 Consumables Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Software & Services
7.4.1 Software & Services Market Trends Analysis (2020-2032)
7.4.2 Software & Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Neuroscience Market Segmentation, by End-Use
8.1 Chapter Overview
8.2 Hospitals
8.2.1 Hospitals Market Trends Analysis (2020-2032)
8.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Diagnostic laboratories
8.3.1 Diagnostic laboratories Market Trends Analysis (2020-2032)
8.3.2 Diagnostic laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Research and Academic Institute
8.4.1 Research and Academic Institute Market Trends Analysis (2020-2032)
8.4.2 Research and Academic Institute Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Neuroscience Market Segmentation, by Technology
9.1 Chapter Overview
9.2 Brain Imaging
9.2.1 Brain Imaging Market Trends Analysis (2020-2032)
9.2.2 Brain Imaging Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Neuro-Microscopy
9.3.1 Neuro-Microscopy Market Trends Analysis (2020-2032)
9.3.2 Neuro-Microscopy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Stereotaxic Surgeries
9.4.1 Stereotaxic Surgeries Market Trends Analysis (2020-2032)
9.4.2 Stereotaxic Surgeries Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Neuro-Proteomic Analysis
9.5.1 Neuro-Proteomic Analysis Market Trends Analysis (2020-2032)
9.5.2 Neuro-Proteomic Analysis Market Size Estimates and Forecasts to 2032 (USD Billion)
9.6 Neuro-Cellular Manipulation
9.6.1 Neuro-Cellular Manipulation Market Trends Analysis (2020-2032)
9.6.2 Neuro-Cellular Manipulation Market Size Estimates and Forecasts to 2032 (USD Billion)
9.7 Others
9.7.1 Others Market Trends Analysis (2020-2032)
9.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Neuroscience Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.2.4 North America Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.5 North America Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.2.6.2 USA Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.6.3 USA Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.2.7.2 Canada Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.7.3 Canada Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.2.8.2 Mexico Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.2.8.3 Mexico Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Neuroscience Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.1.6.2 Poland Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.6.3 Poland Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.1.7.2 Romania Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.7.3 Romania Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Neuroscience Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.4 Western Europe Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.5 Western Europe Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.6.2 Germany Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.6.3 Germany Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.7.2 France Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.7.3 France Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.8.2 UK Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.8.3 UK Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.9.2 Italy Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.9.3 Italy Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.10.2 Spain Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.10.3 Spain Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.13.2 Austria Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.13.3 Austria Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Neuroscience Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.4 Asia Pacific Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.5 Asia Pacific Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.6.2 China Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.6.3 China Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.7.2 India Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.7.3 India Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.8.2 Japan Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.8.3 Japan Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.9.2 South Korea Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.9.3 South Korea Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.10.2 Vietnam Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.10.3 Vietnam Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.11.2 Singapore Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.11.3 Singapore Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.12.2 Australia Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.12.3 Australia Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Neuroscience Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.1.4 Middle East Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.5 Middle East Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.1.6.2 UAE Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.6.3 UAE Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Neuroscience Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.2.4 Africa Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.5 Africa Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Neuroscience Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.6.4 Latin America Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.5 Latin America Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.6.6.2 Brazil Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.6.3 Brazil Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.6.7.2 Argentina Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.7.3 Argentina Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.6.8.2 Colombia Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.8.3 Colombia Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Neuroscience Market Estimates and Forecasts, By Component (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Neuroscience Market Estimates and Forecasts, by End-Use (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Neuroscience Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
11. Company Profiles
11.1 Johnson & Johnson MedTech
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Philips Healthcare
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 Medtronic
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product s/ Services Offered
11.3.4 SWOT Analysis
11.4 GE Healthcare
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Siemens Healthineers
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 AbbVie
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Boston Scientific
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 Cerenovus (Johnson & Johnson)
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 NeuroPace
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Stryker Corporation
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Component
Instruments
Consumables
Software & Services
By End-Use
Hospitals
Diagnostic laboratories
Research and Academic Institute
By Technology
Brain Imaging
Neuro-Microscopy
Stereotaxic Surgeries
Neuro-Proteomic Analysis
Neuro-Cellular Manipulation
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Epilepsy Device Market Size was valued at USD 0.75 billion in 2023 and is expected to reach USD 1.18 billion by 2032 and grow at a CAGR of 5.15% over the forecast period 2024-2032.
The Multiple Myeloma Market size was estimated at USD 24.01 Billion In 2023 & is estimated to reach USD 59.45 Billion by 2032 and increase at a compound annual growth rate of 10.6% between 2024 and 2032.
The global tinnitus management market, valued at USD 3.45 Billion in 2023, is projected to reach USD 5.02 Billion by 2032, growing at a compound annual growth rate CAGR of 4.44% during the forecast period.
The Medical Device Engineering Market size is expected to be valued at USD 10.98 Billion in 2023. It is estimated to reach USD 25.27 Billion by 2032, with a growing CAGR of 9.59% over the forecast period 2024-2032.
The Oral Syringes Market size was USD 350.0 Million in 2023 and is expected to reach USD 1092.57 Million by 2032 and grow at a CAGR of 4.3% by 2024-2032.
The Healthcare Mobility Solutions Market Size was valued at USD 150.19 billion in 2023, and is expected to reach USD 1143.40 billion by 2032, and grow at a CAGR of 25.3% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
